News Releases

Findings indicate the potential for monitoring disease risk through inexpensive, unintrusive continuous measures of skin temperature.

An experimental mRNA vaccine provides protection in preclinical animal models against infection from Borrelia burgdorferi, the bacteria that causes Lyme disease. Results suggest that the vaccine prevents the development of Lyme disease.

Penn Medicine and Penn Engineering expand presence in Wexford’s uCity Square Knowledge Community.

Carl June, MD, has been named a winner of the 2024 Breakthrough Prize in Life Sciences for pioneering the development of CAR T cell therapy, a revolutionary approach to cancer treatment that programs patients’ own immune cells to fight their cancer.

Bob Russell has been named Chief Executive Officer of Penn Presbyterian Medical Center, after serving as acting CEO since September 2022. He succeeds long-time CEO Michele Volpe.

Penn researchers in the Berger Lab have found the blood-brain barrier (BBB) plays a significant role in controlling behavior critical to how ant colonies function. The implications of this research go beyond the world of ants.

A broad new strategy could hold hope for treating virtually all blood cancers with CAR T cell therapy, which is currently approved for five subtypes of blood cancer. A new preclinical, proof-of-concept study details the “epitope-editing” approach.